Price-to-Projected Revenue Ratio: Zomedica Corp (ZOM)

Zomedica Corp. generates revenue through long-term contracts for the supply of consumables for its diagnostic systems. On GURU.Markets, the company's forward P/S clearly reflects market expectations, with the current value equal to 3.60. Market capitalization growth is driven by the scaling of the TRUFORMA and PulseVet platforms, while high margins are sustained by patent protection of unique veterinary developments.
Analytical breakdowns for Zomedica Corp.

The forward P/S ratio relates the current market value of Zomedica Corp. (ZOM) to expected revenue, allowing for an assessment of the asset's fair value relative to its income-generating potential. By analyzing the projected P/S trend, an investor can determine the scaling efficiency of the TRUFORMA and PulseVet systems, where a deviation of the multiple from industry norms would indicate an overvaluation or undervaluation of the company's expansion within the B2B veterinary segment.